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Abstract
Cannabis smoking can create respiratory problems. Vaporizers heat cannabis to release active
cannabinoids, but remain cool enough to avoid the smoke and toxins associated with combustion.
Vaporized cannabis should create fewer respiratory symptoms than smoked cannabis. We
examined self-reported respiratory symptoms in participants who ranged in cigarette and cannabis
use. Data from a large Internet sample revealed that the use of a vaporizer predicted fewer
respiratory symptoms even when age, sex, cigarette smoking, and amount of cannabis used were
taken into account. Age, sex, cigarettes, and amount of cannabis also had significant effects. The
number of cigarettes smoked and amount of cannabis used interacted to create worse respiratory
problems. A significant interaction revealed that the impact of a vaporizer was larger as the amount
of cannabis used increased. These data suggest that the safety of cannabis can increase with the use
of a vaporizer. Regular users of joints, blunts, pipes, and water pipes might decrease respiratory
symptoms by switching to a vaporizer
Background
Cannabis smoke contains gaseous and particulate matter
with the potential to create symptoms of respiratory prob-
lems [1]. Although cannabis creates fewer problems than
cigarette smoking [2], increasing its safety has the poten-
tial to improve quality of life. One step toward increasing
the safety of cannabis involves the use of vaporizers.
Vaporizers heat cannabis to temperatures that release can-
nabinoids in a fine mist without creating the toxins asso-
ciated with combustion [3,4]. Although vaporizers are not
common knowledge in popular culture, a recent photo-
graph of one appeared in the New England Journal of
Medicine [5], and information about the machine is
becoming more available. A vaporizer has the potential to
increase the safety of cannabis use, but data from human
users appear only rarely [4].
The potential for cannabis-induced lung problems is par-
ticularly important in light of frequent concurrent tobacco
smoking. Cannabis use may prove especially detrimental
in the production of respiratory symptoms in cigarette
smokers. For example, one study revealed increased respi-
ratory symptoms in cannabis dependent 21-year-olds, but
particularly in those who also smoked cigarettes. Canna-
bis dependence in the absence of cigarette use led to
symptoms comparable to smoking 1–10 cigarettes per
day, but quickly escalated when cannabis and tobacco
were combined [6].
Method
We sought to identify the impact of vaporizers on respira-
tory symptoms. In an effort to target frequent cannabis
users, three organizations committed to reforming drug
laws were asked to send a query to their mailing lists for
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participation in a survey. Participants responded to an
email request and had a chance to win a cash prize.
Approximately 9,000 people replied, but we focused on
those who had used cannabis at least once in the previous
month. (More details of the data collection appear in a
paper addressing other aspects of this sample [7].) In an
effort to minimize the impact of other sources of respira-
tory symptoms, only those respondents who did not have
cystic fibrosis or asthma and had never inhaled other
drugs (inhalants, heroin, methamphetamine, or crack
cocaine) were included. Those who reported that their pri-
mary method of administration of cannabis was oral
ingestion were also omitted, because eating the plant
should have no smoke-inhalation-induced respiratory
effects.
Participants
The 6,883 people who qualified included 4,493 men
(65.3%) and 2,390 women. Ages ranged from 18 to 88
(Mean = 31.3, SD = 12.4). Education ranged from some
high school to advanced degrees, with a median of some
college but not a degree. Median income was $20,000 to
$40,000 per year. Respondents were primarily Caucasian
(87%) but included African Americans (1%), Native
Americans (3%), Asians (3%) Latinos (4%), and people
of mixed race (2%). Participants reported that their first
cannabis use was at a mean age of 16.7 (SD = 4.2).
Measures
Respiratory symptoms
Participants reported respiratory symptoms by answering
six questions: Do you usually have a cough? Does your
chest sound wheezy or whistling other than from colds?
Are you troubled by shortness of breath when hurrying on
the level ground or walking up a slight hill? Do you have
to walk slower than most people your own age on the
level ground because of breathlessness? Do you cough up
phlegm in the morning? and Do you wake up at night
with tightness in your chest? These questions revealed res-
piratory problems in cannabis-dependent individuals in
previous work [6]. Symptoms were not particularly com-
mon (mean of the total symptom count = 0.80, SD = 1.1),
but ranged from 0 to 6.
The sum of these items had significant skew that would
preclude the use of parametric statistics, so we created two
groups of participants: those who did (N = 3,016) and did
not (N = 3,867) report respiratory problems. This dichot-
omized outcome served as the dependent variable.
Vaporizer use
Participants reported the technique they used most fre-
quently when ingesting marijuana, and chose from
blunts, joints, water pipes, pipes, edibles, vaporizers, and
other. Only 152 participants (2.2%) reported vaporizing
as their primary method for cannabis use.
Marijuana use
Although assessing the frequency of marijuana use has
proven comparable to assessing the frequency of use for
other drugs, assessing the quantity of consumption
remains quite difficult. Standard units comparable to
those found with alcohol or cigarettes are unavailable.
Because respiratory effects of marijuana should covary
with the amount used rather than the simple frequency of
use, we asked participants to estimate the amount of mar-
ijuana they consumed per week in 1-gram joint equiva-
lents. This rough estimate is necessarily imperfect, but has
proven useful in previous work [8]. Participants reported
amount of cannabis use in one-gram joint equivalents,
which averaged 9.4 grams per week (SD = 11.9).
Cigarettes
Those who smoked cigarettes (4,829) began at a mean age
of 16.0 (SD = 3.4). Cigarette smoking was generally light.
Mean cigarettes per day was 8.6 (SD = 10.7) but ranged as
high as 4 packs per day.
Results
A simple chi-square test revealed that vaporizer users were
less likely to report respiratory problems than participants
who did not vaporize, with 100 of 152 vaporizer users
(65.8%) reporting no respiratory problems, compared to
3767 of 6731 (56.0%), chi-square (1) = 5.8, p < .05. This
analysis provided a rough look at the potential for vapor-
izers, and suggested that the machines could improve res-
piratory symptoms. Nevertheless, this analytic approach
did not account for important covariates or address poten-
tial interactions, so we used logistic regression. We com-
puted interactions by centering the variables to correct for
non-essential multicollinearity and then multiplying [9].
We report the full model with all two-way interactions
and the three-way interaction present, but deleting any of
these effects did not change the pattern of results. A logis-
tic regression analysis with age and sex as covariates
revealed main effects for cigarettes, cannabis use, and
vaporizer use. The interaction of cigarettes and marijuana
was significant, as revealed in previous work [6]. In addi-
tion the interaction of marijuana use and vaporizer use
was significant, all p-values < .05. (See Table 1.)
Discussion
These results suggest that the respiratory effects of canna-
bis can decrease with the use of a vaporizer. The data
reveal that respiratory symptoms like cough, phlegm, and
tightness in the chest increase with cigarette use and can-
nabis use, but are less severe among users of a vaporizer.
Because a sample this large can produce statistically signif-
icant effects that might not be clinically meaningful, aHarm Reduction Journal 2007, 4:11 http://www.harmreductionjournal.com/content/4/1/11
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focus on odds ratios could prove fruitful. The odds ratio
suggests that vaporizer users are only 40% as likely to
report respiratory symptoms as users who do not vapor-
ize, even when age, sex, cigarette use, and amount of can-
nabis consumed are controlled. The use of cigarettes in
conjunction with cannabis exacerbated symptoms, as
found in previous work [6]. The interaction between
vaporizer use and cannabis consumption also appeared,
suggesting that a vaporizer should have more impact on
respiratory symptoms in people who use more marijuana.
Odds ratios suggest that these effects are relatively small,
but interactions often prove difficult to detect at all [9].
Several important limitations of these data deserve men-
tion, particularly those related to sampling, Internet
reporting, limitations of our measures, and the lack of
random assignment to vaporizer use. In an effort to find
regular users of cannabis, we targeted people with a poten-
tial interest in changing cannabis policy. These individu-
als might have consciously or unconsciously minimized
their reports of symptoms that might cast cannabis in a
negative light. Nevertheless, literally thousands of partici-
pants admitted to experiencing respiratory symptoms.
The symptoms covaried with cannabis use, cigarette use,
and the interaction of the two, as work with samples gath-
ered in other ways has revealed [6]. These results suggest
that reports among these participants are comparable to
those found in other work. Any bias in reporting remains
a problem, and only further work can help address this
issue.
Vaporizer users might be more inclined to minimize res-
piratory symptoms than people who smoke cannabis in
other ways. The price of a vaporizer can range as high as
hundreds of dollars. Vaporizers also lack some of the con-
venience of other methods of marijuana use. Users who
have spent this much money and effort might minimize
reports of their respiratory symptoms, consciously or
inadvertently, in an effort to justify their actions. Only a
more objective measure of respiratory function that does
not rely on self-report can sidestep this potential problem.
Laboratory measures of lung function would make a nice
addition to further work on this topic. Nevertheless,
roughly 1/3 of the participants who used a vaporizer (52/
152) did report symptoms, suggesting that self-report
biases on symptom reports likely does not account for the
entire phenomenon.
The use of the Internet for this type of work has advan-
tages and disadvantages as well. This approach might lead
individuals who are unwilling to travel to the laboratory
to participate, potentially increasing generalizability.
Heavy users with severe symptoms might be particularly
disinclined to participate without the convenience of the
Internet.
Recent work also suggests that people report more drug
use while using the Internet than they do on standard
paper-and-pencil measures [10]. Nevertheless, because
Internet access was required for participation, these data
might not generalize to meaningful subsets of the popula-
tion without such access.
Our measures of vaporizer use and respiratory symptoms
could also have been more detailed. A single question
about the primary technique used for administering can-
nabis neglects potentially meaningful variation in vapor-
izer use. Some participants might use a vaporizer
primarily but also smoke cannabis. In contrast, other par-
ticipants might use a vaporizer exclusively. Both of these
groups of participants would end up in the group who
uses a vaporizer primarily. Vaporizers come in several
forms, including conduction-style machines that employ
a hot plate as well as convection-style devices that use
warmed air. The efficacy of these different machines could
vary substantially, but we could not address the question
with the current data. These limitations, however, should
decrease power rather than create a spurious result. By
lumping participants who occasionally smoke cannabis
into the same group with those who vaporize exclusively,
Table 1: Predicting Respiratory Symptoms (N = 6,883)
Predictor B Standard Error Wald Test Odds Ratio
Age -0.013 .003 19.2* 0.98
Sex 0.351 .066 28.5* 1.42
Cigarettes 0.069 .004 371.9* 1.07
Marijuana 0.021 .003 42.9* 1.02
Vaporizer -0.911 .424 4.6* 0.40
Cigarettes × Marijuana -0.158 .035 20.4* 0.85
Vaporizer × Cigarettes -0.025 .035 0.5 0.98
Vaporizer × Marijuana 0.072 .035 4.2* 1.07
Vaporizer × Cigarettes × Marijuana -0.003 .003 0.8 0.99
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we actually weaken the ability to detect effects. Including
any type of vaporizer, no matter how effective, also has
the potential to weaken effects. In a sense, the current
study's estimate of the effect of a vaporizer on respiratory
symptoms might be an underestimate of the improve-
ment that could arise from a good vaporizer used as the
exclusive method for ingesting cannabis. We also did not
assess the length of time each participant had used a
vaporizer. A vaporizer's impact might grow more dramatic
with longer use. The assessment of respiratory symptoms
was also not particularly elaborate, but the same measures
revealed a significant impact of cannabis and cigarettes in
this sample and in other work [6].
Finally, the use of a vaporizer was not randomly assigned.
The possibility exists that cannabis users who choose a
vaporizer might engage in a host of other behaviors
designed to minimize respiratory symptoms, or simply be
more health conscious in general. Like any correlational
study, this one cannot address the role of causality. The
current data are consistent, however, with the idea that
cannabis vaporizers can decrease respiratory symptoms in
regular users of the plant. A better test of a vaporizer's
potential for minimizing problems would require recruit-
ing cannabis smokers who report respiratory troubles,
randomly assigning a group to use a vaporizer, and assess-
ing any decrease in symptoms. The current data suggest
that such an intervention could prove helpful.
Although the use of a vaporizer has the potential to
increase the safety of cannabis as far as respiratory symp-
toms are concerned, pulmonary problems are not the
only potential negative consequences of the plant.
Reviews suggest that 9–12% of cannabis users develop
symptoms of dependence [11]. Cannabis can lead to
impaired driving skills [12], and heavy use in adolescence
might create deviant brain structure [13] as well as
decreases in intelligence [14]. A vaporizer offers no pro-
tection against these negative consequences. Nevertheless,
a vaporizer has considerable potential for increasing can-
nabis drug safety by minimizing pulmonary troubles.
Competing interests
ME is affiliated with organizations devoted to changing
cannabis laws.
Authors' contributions
ME contributed to study design, coordination and super-
vision, data analysis and interpretation, and drafted the
manuscript. SSB participated in study design and coordi-
nation and helped draft the manuscript.
Acknowledgements
This work was funded by a grant from the Marijuana Policy Project. Special 
thanks to Elana B. Gordis for continued support. We thank two anonymous 
reviewers for courteous and helpful comments.
References
1. Tashkin DP, Baldwin GC, Sarafian T, Dubinett S, Roth MD: Respira-
tory and immunologic consequences of marijuana smoking.
J Clin Pharmacol 2002, 42(Suppl 11):71S-81S.
2. Melamede R: Cannabis and tobacco smoke are not equally car-
cinogenic.  Harm Reduction Journal 2005, 2:21.
3. Gieringer D, St Laurent J, Goodrich S: Cannabis vaporizer com-
bines efficient delivery of THC with effective suppression of
pyrolytic compounds.  Journal of Cannabis Therapeutics 2004,
4:7-27.
4. Hazekamp A, Ruhaak R, Zuurman L, van Gerven J, Verpoorte R: Eval-
uation of a vaporizing device (Volcano) for the pulmonary
administration of tetrahydrocannabinol.  J Pharm Sci 2006,
95:1308-1317.
5. Okie S: Medical marijuana and the Supreme Court.  NEJM
2005, 353(7):648-651.
6. Taylor DR, Poulton R, Moffitt TE, Ramankutty P, Sears MR: The res-
piratory effects of cannabis dependence in young adults.
Addiction 2000, 95:1669-1677.
7. Barnwell SS, Earleywine M, Wilcox R: Cannabis, motivation, and
life satisfaction in an internet sample.  Subst Abuse Treat Prev Pol-
icy 2006, 1:2.
8. Reinarman C, Cohen PDA, Kaal HL: The limited relevance of
drug policy: Cannabis in Amsterdam and in San Francisco.
Am J Public Health 2004, 94:836-842.
9. Aiken L, West S: Multiple Regression: Testing and Interpreting Interactions
Newbury Park, CA: Sage Press; 1991. 
10. Wang YC, Lee CM, Lew-Ting CY, Hsiao CK, Chen DR, Chen WJ:
Survey of substance use among high school students in Tai-
pei: web-based questionnaire versus paper-and-pencil ques-
tionnaire.  J Adolesc Health 2005, 37:289-295.
11. Earleywine M: Understanding Marijuana New York: Oxford University
Press; 2005. 
12. Liguori A: Marijuana and driving: trends, design issues, and
future recommendations.  In Pot Politics Edited by: Earleywine M.
New York: Oxford University Press; 2007. 
13. Wilson W, Mathew R, Turkington T, Hawk T, Coleman RE, Proven-
zale J: Brain morphological changes and early marijuana use:
a magnetic resonance and positron emission tomography
study.  J Addict Dis 2000, 19:1-22.
14. Fried P, Watkinson B, James D, Gray R: Current and former mar-
ijuana use: preliminary findings of a longitudinal study of
effects on IQ in young adults.  CMAJ 2002, 166:887-891.